FDA Pulls Another COVID-19 Rapid Antibody Test Over Performance Concerns
Executive Summary
Autobio’s test reportedly only correctly identified half the positive SARS-CoV-2 antibody samples in an NIH evaluation.
You may also be interested in...
Beckman Coulter Addresses COVID-19 Testing From Multiple Angles
The company expects testing for IgM antibodies will be useful in areas where PCR testing is not keeping up with demand.
FDA Pulls Chembio’s Rapid Test As Purge Of ‘Inaccurate’ Antibody Tests Continues
Chembio’s stock opened down 60% the day after the FDA’s decision to revoke its EUA for the first US rapid test for antibodies to SARS-CoV-2.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.